Mesna Altan

Mesna, the active ingredient in Mesna Altan, is a thiol protective agent presented as a sterile solution (strength not specified) for endotracheopulmonary inhalation use. It is employed to prevent urotoxic damage caused by the chemotherapy metabolites acrolein and to protect mucosal surfaces. GNH USA supplies Mesna Altan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, transplant centres, pharmacies, research institutions and clinics worldwide through reliable logistics with consistent quality assurance.

Mesna is used to protect the urinary tract and mucosal surfaces during chemotherapy that generates the toxic metabolite acrolein. - Hemorrhagic cystitis (cyclophosphamide therapy): reduces the incidence and severity of bladder bleeding. - Hemorrhagic cystitis (ifosfamide therapy): provides uroprotection against acrolein‑induced damage. - Mucosal protection during chemotherapy: safeguards oral and gastrointestinal mucosa from toxic metabolites.

Mesna may be associated with a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nausea - Vomiting - Headache - Mild skin rash - Altered taste perception - Low‑grade fever

Serious or Rare Side Effects: - Anaphylactic reaction - Stevens‑Johnson syndrome - Hemolytic anemia - Acute renal failure - Pulmonary edema

When prescribing Mesna, clinicians should observe several safety considerations to minimise risk. - Renal function assessment: evaluate baseline kidney function before initiating therapy. - Pulmonary status review: ensure adequate respiratory function for inhalation administration. - Hypersensitivity monitoring: watch for signs of allergic reaction during treatment. - Timing with chemotherapy: coordinate dosing with cyclophosphamide or ifosfamide to maintain protective effect. - Pregnancy and lactation counseling: discuss unknown safety profile with women of child‑bearing potential. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Mesna can interact with other medicines, requiring attention to timing and monitoring.

Major Interactions (Avoid): - Cyclophosphamide/Ifosfamide: dosing must be synchronized to avoid reduced chemotherapy efficacy. - Nitrofurantoin: concurrent use may increase risk of hemolysis. - High‑dose thiol‑containing agents: may cause additive toxicity.

Moderate Interactions (Monitor Closely): - Aminoglycoside antibiotics: monitor renal function due to combined nephrotoxic potential. - Loop diuretics: watch electrolyte balance and urine output. - Warfarin: observe INR values as Mesna may affect anticoagulant control.